FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS

Purpose. To analyze concomitant pathology contributing to filamentary keratitis and its incidence and to evaluate an effectiveness of different treatment regimens.Material and methods. The examination included 30 patients (60 eyes) with filamentary keratitis. All patients were divided into 3 groups...

Full description

Bibliographic Details
Main Authors: D. Y. Maychuk, I. A. Pronkin, Y. V. Kolubelova
Format: Article
Language:Russian
Published: Publishing house "Ophthalmology" 2015-10-01
Series:Офтальмохирургия
Subjects:
Online Access:https://www.ophthalmosurgery.ru/jour/article/view/53
id doaj-6827f1f8f73b465e845087dfe414bda4
record_format Article
spelling doaj-6827f1f8f73b465e845087dfe414bda42021-07-28T13:53:35ZrusPublishing house "Ophthalmology"Офтальмохирургия0235-41602312-49702015-10-0104354053FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENSD. Y. Maychuk0I. A. Pronkin1Y. V. Kolubelova2The S. Fyodorov Eye Microsurgery Federal State Institution, MoscowThe S. Fyodorov Eye Microsurgery Federal State Institution, MoscowThe S. Fyodorov Eye Microsurgery Federal State Institution, MoscowPurpose. To analyze concomitant pathology contributing to filamentary keratitis and its incidence and to evaluate an effectiveness of different treatment regimens.Material and methods. The examination included 30 patients (60 eyes) with filamentary keratitis. All patients were divided into 3 groups depending on treatment regimen: group 1 – Vitabact, Hylozar-comod, Balarpan, Corneregel 4 t/d; group 2 – the same reparative treatment and dexamethasone; group 3 – the same reparative treatment and 0.05% cyclosporine A. Among investigative methods there were following diagnostic methods: patients’ questionnaire, biomicroscopy, 5-region corneal fluorescein staining scale, Shirmer test – 1, TBUTtest. Follow-up period was 6 months.Results. Concomitant diseases were revealed in 100% of patients (89.5% – endocrine pathology or rheumatoid diseases). Shirmer test results were variable and no appropriateness and dependency on treatment regimen were found. All other tests detected data increased dramatically at the 2-3 weeks of follow-up in the groups 1 and 2, but dropped down also very quickly after 1 month. In the group 3 improvement indices were slowly, but stayed stable for the whole follow-up period.Conclusion. 1. Endocrine pathology or rheumatoid diseases or their combination appear in 89.5% of patients. 2. Dexamethasone as a component of combined therapy contributed to rapid filaments’ resorption and to stop symptoms of dry eye syndrome. 3. Restasis promotes a stable remission.https://www.ophthalmosurgery.ru/jour/article/view/53filamentary keratitis0.05% cyclosporine a
collection DOAJ
language Russian
format Article
sources DOAJ
author D. Y. Maychuk
I. A. Pronkin
Y. V. Kolubelova
spellingShingle D. Y. Maychuk
I. A. Pronkin
Y. V. Kolubelova
FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
Офтальмохирургия
filamentary keratitis
0.05% cyclosporine a
author_facet D. Y. Maychuk
I. A. Pronkin
Y. V. Kolubelova
author_sort D. Y. Maychuk
title FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
title_short FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
title_full FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
title_fullStr FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
title_full_unstemmed FILAMENTARY KERATITIS ETIOLOGY ANALYSIS, ITS COMBINATION WITH SYSTEMIC DISEASES AND ETIOPATHOGENIC TREATMENT REGIMENS
title_sort filamentary keratitis etiology analysis, its combination with systemic diseases and etiopathogenic treatment regimens
publisher Publishing house "Ophthalmology"
series Офтальмохирургия
issn 0235-4160
2312-4970
publishDate 2015-10-01
description Purpose. To analyze concomitant pathology contributing to filamentary keratitis and its incidence and to evaluate an effectiveness of different treatment regimens.Material and methods. The examination included 30 patients (60 eyes) with filamentary keratitis. All patients were divided into 3 groups depending on treatment regimen: group 1 – Vitabact, Hylozar-comod, Balarpan, Corneregel 4 t/d; group 2 – the same reparative treatment and dexamethasone; group 3 – the same reparative treatment and 0.05% cyclosporine A. Among investigative methods there were following diagnostic methods: patients’ questionnaire, biomicroscopy, 5-region corneal fluorescein staining scale, Shirmer test – 1, TBUTtest. Follow-up period was 6 months.Results. Concomitant diseases were revealed in 100% of patients (89.5% – endocrine pathology or rheumatoid diseases). Shirmer test results were variable and no appropriateness and dependency on treatment regimen were found. All other tests detected data increased dramatically at the 2-3 weeks of follow-up in the groups 1 and 2, but dropped down also very quickly after 1 month. In the group 3 improvement indices were slowly, but stayed stable for the whole follow-up period.Conclusion. 1. Endocrine pathology or rheumatoid diseases or their combination appear in 89.5% of patients. 2. Dexamethasone as a component of combined therapy contributed to rapid filaments’ resorption and to stop symptoms of dry eye syndrome. 3. Restasis promotes a stable remission.
topic filamentary keratitis
0.05% cyclosporine a
url https://www.ophthalmosurgery.ru/jour/article/view/53
work_keys_str_mv AT dymaychuk filamentarykeratitisetiologyanalysisitscombinationwithsystemicdiseasesandetiopathogenictreatmentregimens
AT iapronkin filamentarykeratitisetiologyanalysisitscombinationwithsystemicdiseasesandetiopathogenictreatmentregimens
AT yvkolubelova filamentarykeratitisetiologyanalysisitscombinationwithsystemicdiseasesandetiopathogenictreatmentregimens
_version_ 1721270383390228480